Effects of Intravenous Ketamine on Posttraumatic Stress Disorder (PTSD): A Systematic Review
- PMID: 41326978
- DOI: 10.1111/acps.70053
Effects of Intravenous Ketamine on Posttraumatic Stress Disorder (PTSD): A Systematic Review
Abstract
Introduction: Posttraumatic stress disorder (PTSD) is a mental disorder resulting from exposure to traumatic events. Evidence suggests that ketamine may be efficacious in treating PTSD, however, ketamine's mechanisms in treating PTSD remain unclear. Herein, this review aims to evaluate the clinical outcomes of ketamine treatment in persons with PTSD and investigate the possible neurobiological mechanisms underlying ketamine's therapeutic effect in PTSD.
Methods: A systematic search was conducted on PubMed and OVID (MEDLINE, Embase, PsychINFO) from inception until September 2025. Randomized controlled trials reporting on the effects of intravenous ketamine to treat PTSD were included.
Results: Seven studies with a total of 323 participants were included in this review. Ketamine administration meaningfully improved PTSD symptoms in two trials as evidenced by significant improvement on the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) and the Impact of Event Scale-Revised (IES-R) compared to control/placebo. Multi-infusion administration schedules achieved greater clinical outcomes when compared to single-dose administration schedules. Preliminary evidence suggests that repeated lower doses (0.2mg/kg) of ketamine were more efficacious in sustaining treatment effects than standard doses (0.5mg/kg). For persons receiving ketamine, an association was observed between top-down inhibition of the amygdala originating in the ventromedial prefrontal cortex (vmPFC) and symptom improvement.
Conclusion: Our results suggest that intravenous ketamine may be efficacious in the treatment of PTSD. Subsequent studies should attempt to evaluate the additive effect of combining ketamine with psychotherapeutic interventions as well as determining mechanistic pathways mediating symptom relief in persons with PTSD.
Keywords: Ketalar; N‐methyl‐D‐aspartate (NMDA) receptor; ketamine; posttraumatic stress symptoms; post‐traumatic stress disorder; trauma‐related stress.
© 2025 The Author(s). Acta Psychiatrica Scandinavica published by John Wiley & Sons Ltd.
References
-
- E. Compean and M. Hamner, “Posttraumatic Stress Disorder With Secondary Psychotic Features (PTSD‐SP): Diagnostic and Treatment Challenges,” Progress in Neuro‐Psychopharmacology and Biological Psychiatry 88 (2019): 265–275.
-
- C. Schrader and A. Ross, “A Review of PTSD and Current Treatment Strategies,” Missouri Medicine 118, no. 6 (2021): 546–551.
-
- R. H. Pietrzak, R. B. Goldstein, S. M. Southwick, and B. F. Grant, “Prevalence and Axis I Comorbidity of Full and Partial Posttraumatic Stress Disorder in the United States: Results From Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions,” Journal of Anxiety Disorders 25, no. 3 (2011): 456–465.
-
- H. F. Guillén‐Burgos and K. Gutiérrez‐Ruiz, “Avances Genéticos en el Trastorno Por Estrés Postraumático,” Revista Colombiana de Psiquiatría 47, no. 2 (2018): 108–118.
-
- J. Schein, C. Houle, A. Urganus, et al., “Prevalence of Post‐Traumatic Stress Disorder in the United States: A Systematic Literature Review,” Current Medical Research and Opinion 37, no. 12 (2021): 2151–2161.
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous
